1. Home
  2. CYTK vs STRL Comparison

CYTK vs STRL Comparison

Compare CYTK & STRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$54.70

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Logo Sterling Infrastructure Inc.

STRL

Sterling Infrastructure Inc.

HOLD

Current Price

$246.14

Market Cap

11.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
STRL
Founded
1997
1955
Country
United States
United States
Employees
N/A
1740
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.9B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
CYTK
STRL
Price
$54.70
$246.14
Analyst Decision
Buy
Strong Buy
Analyst Count
22
8
Target Price
$107.39
★ $693.43
AVG Volume (30 Days)
★ 1.6M
938.4K
Earning Date
11-04-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 13.42
EPS
N/A
★ 15.01
Revenue
$13,368,000.00
★ $957,958,000.00
Revenue This Year
$79.67
$88.49
Revenue Next Year
$172.23
$21.24
P/E Ratio
★ N/A
$18.93
Revenue Growth
N/A
★ 38.81
52 Week Low
$58.25
$279.78
52 Week High
$88.31
$1,005.68

Technical Indicators

Market Signals
Indicator
CYTK
STRL
Relative Strength Index (RSI) 52.28 26.04
Support Level $63.96 N/A
Resistance Level $66.93 $469.22
Average True Range (ATR) 2.04 29.43
MACD 0.50 -7.52
Stochastic Oscillator 86.71 2.61

Price Performance

Historical Comparison
CYTK
STRL

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About STRL Sterling Infrastructure Inc.

Sterling Infrastructure Inc operates through subsidiaries within three segments: E-Infrastructure, Transportation, and Building Solutions in the United States, mainly across the Southern, Northeastern, Mid-Atlantic, and Rocky Mountain regions and the Pacific Islands. E-Infrastructure Solutions generates maximum revenue and provides site development and mission-critical electrical services for data centers, manufacturing, distribution centers, warehousing, and power generation. Transportation Solutions includes infrastructure and rehabilitation projects for highways, airports, ports, rail, and storm drainage systems. Building Solutions includes residential and commercial concrete foundations, parking structures, plumbing services, and surveys for new single-family residential builds.

Share on Social Networks: